Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Eczema, Targeted Therapeutics, and Allergy Diagnostics: The Need for Greater Clarity on What We Are Treating. Journal of the European Academy of Dermatology and Venereology : JEADV Chen, J. K., Honari, G. n., Silverberg, J. I. 2020
Abstract
Until recently, step-up therapy in atopic dermatitis (AD) included primarily off-label use of phototherapy, systemic immunosuppressants and/or corticosteroids. These broadly impact the immune system and show efficacy across a gamut of inflammatory skin diseases, albeit with potential serious adverse-events. Recently, dupilumab was approved as the first biologic agent in AD and demonstrated better efficacy and safety than prior off-label therapies.
View details for DOI 10.1111/jdv.16445
View details for PubMedID 32277506